AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x L , Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Targeting Bcl-2 family members upregulated in multiple cancers has emerged as an important area of cancer therapeutics. While venetoclax, a Bcl-2-selective inhibitor, has had success in the clinic, another family member, Bcl-x , has also emerged as an important target and as a mechanism of resistanc...

Ausführliche Beschreibung